<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03751228</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-068</org_study_id>
    <nct_id>NCT03751228</nct_id>
  </id_info>
  <brief_title>A Taste Assessment of BMS-986165 in Healthy Participants</brief_title>
  <official_title>An Open-Label Taste Assessment of BMS-986165 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the taste characteristics of BMS-986165 formulations,
      alone and mixed, in order to develop a pediatric oral form of BMS-986165.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 11, 2018</start_date>
  <completion_date type="Actual">November 26, 2018</completion_date>
  <primary_completion_date type="Actual">November 26, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Taste properties of BMS-986165 alone &amp; in prototypes to determine Aromatic identity will be measured using the Flavor Profile of the Flavor Leadership Criteria</measure>
    <time_frame>Approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Taste properties of BMS-986165 alone &amp; in prototypes to determine amplitude will be measured using the Flavor Profile of the Flavor Leadership Criteria</measure>
    <time_frame>Approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Taste properties of BMS-986165 alone &amp; in prototypes to determine mouth-feel will be measured using the Flavor Profile of the Flavor Leadership Criteria</measure>
    <time_frame>Approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Taste properties of BMS-986165 alone &amp; in prototypes to determine off-notes will be measured using the Flavor Profile of the Flavor Leadership Criteria</measure>
    <time_frame>Approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Taste properties of BMS-986165 alone &amp; in prototypes to determine aftertaste will be measured using the Flavor Profile of the Flavor Leadership Criteria</measure>
    <time_frame>Approximately 2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>BMS-986165 taste evaluation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986165 taste evaluation using Active Pharmaceutical Ingredient (API) and Prototypes of the API containing various flavors and sweeteners</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165</intervention_name>
    <description>Swish and expectorate after tasting</description>
    <arm_group_label>BMS-986165 taste evaluation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Pharmaceutical Ingredient</intervention_name>
    <description>Swish and expectorate after tasting</description>
    <arm_group_label>BMS-986165 taste evaluation</arm_group_label>
    <other_name>API</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  WOCBP must agree to follow instructions for method(s) of contraception for 5
             half-lives of BMS-986165 (2 days) plus 30 days (duration of ovulatory cycle) for a
             total of 32 days after each tasting day.

          -  Males who are sexually active with WOCBP must agree to follow instructions for
             method(s) of contraception 5 half-lives of the study drug (2 days) after each tasting
             day.

        Exclusion Criteria:

          -  A known sensitivity to BMS-986165

          -  A history of any illness that, in the opinion of the investigator, might confound the
             results of the study or pose an additional risk in administering study drug(s) to the
             participant. This may include but is not limited to: a history of relevant drug or
             food allergies; history of cardiovascular or central nervous system disease; history
             or presence of clinically significant pathology; or history of mental disease

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Senopsys</name>
      <address>
        <city>Woburn</city>
        <state>Massachusetts</state>
        <zip>01801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2018</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BMS-986165</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

